65 results
S-8
EX-99.3
NGNE
Neurogene Inc
20 Feb 24
Registration of securities for employees
4:16pm
will be returned to such Participant or, in the case of his or her death, to the person or persons entitled thereto under Section 15 (without interest … and cash, if any, from the Participant’s notional account under the Plan in the event of such Participant’s death subsequent to an Exercise Date on which
S-8
EX-99.1
NGNE
Neurogene Inc
20 Feb 24
Registration of securities for employees
4:16pm
, death, retirement, authorized leave of absence or any other change or purported change in a Participant’s Service Provider status and the extent … period immediately following such “separation from service” (or, if earlier, until the date of death of the specified employee) and shall instead
S-8
EX-99.2
NGNE
Neurogene Inc
20 Feb 24
Registration of securities for employees
4:16pm
be exercised following the Participant’s death by the Participant’s beneficiaries or as permitted by the Committee and (b) as permitted by the Committee … (or following the assigning Participant’s death, by the Participant’s beneficiaries or as otherwise permitted by the Committee) and provided further
8-K
EX-10.23
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
instead be paid on the next regular payroll date following the expiration of
such six (6) month period or, if earlier, upon Employee’s death (except
8-K
EX-10.6
o61 o1w2pvw
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.22
1orp3ic98zom1ddjo60t
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-99.4
z0jdzzntnor1s88o14i
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-3.2
cq67t d00
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.24
9bkq4r0d
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.21
zn4t h7ided
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-3.3
y4ilkni1bp6xf9gidmy
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
425
6yr803wo3eb
4 Dec 23
Business combination disclosure
5:14pm
8-K
EX-10.1
7d5qy
4 Dec 23
Other Events
5:10pm
S-4/A
vtcwm6
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
S-4/A
EX-10.31
7jtrg9ikdanf9
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
S-4/A
EX-10.29
d21da6z1
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm